Recombinant Human Tissue-type plasminogen activator (PLAT), partial

Name: Recombinant Human Tissue-type plasminogen activator (PLAT), partial
Brand: CUSABIO
SKU: CSB-EP018120HU

中文名稱：

人PLAT重組蛋白
品名簡稱：

Recombinant Human PLAT protein, partial
貨號：

CSB-EP018120HU
說明書：

MSDS Datasheet
規格：

￥1344
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產品詳情
產品評價
相關產品
問答及客戶評論
靶點詳情

產品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

PLAT
Uniprot No.：

P00750
別名：

Alteplase; DKFZp686I03148; Plasminogen activator tissue; Plasminogen activator tissue type; PLAT; Reteplase; t PA; T Plasminogen Activator; t-PA; T-plasminogen activator; Tissue plasminogen activator (t PA); Tissue type plasminogen activator; Tissue-type plasminogen activator chain B; tPA; TPA_HUMAN; TPA1
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
來源：

E.coli
分子量：

74.3kDa
表達區域：

36-556aa
氨基酸序列

SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWI
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

N-terminal 6xHis-SUMO-tagged
產品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
產品描述：

The production of this recombinant Human PLAT protein is just like all recombinant proteins. The process involved transfecting E.coli cells with DNA vector containing the template of recombinant DNA. The E.coli cells containing the template were then cultured so that they could transcribe and translate the PLAT protein. N-terminal 6xHis-SUMO tag was used in the process. The purity is 90% determined by SDS-PAGE.
PLAT is a gene providing instructions for making a protein named tissue-type plasminogen activator (also known as a t-plasminogen activator, tPA). This protein is a serine protease that converts a zymogen plasminogen into an active serine protease, namely, plasmin (the primary enzyme involved in dissolving blood clots). tPA is involved in blood coagulation, cellular protein modification process, fibrinolysis, response to hypoxia, smooth muscle cell migration and trans-synaptic signaling by BDNF, modulating synaptic transmission.
Datasheet & COA：

Please contact us to get it.

產品評價

問答及客戶評論

■ 常見問題解答

We would like to know the components of the buffer for item CSB-EP018120HU. Would you have this information on file that you could share?
Would the components of the buffer be the same if they ordered 10 mg?

Thanks for your inquiry. The Datasheet&COA is attached which includes the buffer components. We could guarantee 10mg from same lot, so the buffer components will be the same.

收起更多

靶點詳情

功能：

Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. During oocyte activation, plays a role in cortical granule reaction in the zona reaction, which contributes to the block to polyspermy.
基因功能參考文獻：
1. These findings provides evidence that gene-gene interactions between p11, tPA and BDNF are all associated with post stroke depression. PMID: 29028593
2. Underexpression of Tissue plasminogen activator is associated with diabetic foot syndrome. PMID: 28193577
3. By mediating the tPA response in macrophages, the NMDA-R provides a pathway by which the fibrinolysis system may regulate innate immunity. PMID: 28684538
4. Data suggest that protein aggregates interact with tissue-type plasminogen activator and plasminogen to efficiently generate plasmin; this aggregate-bound plasmin is shielded from inhibition by alpha-2-antiplasmin and degrades protein aggregates to release smaller, soluble but relatively hydrophobic peptide fragments; these fragments bind to and are cytotoxic to microglia (by not vascular endothelial cells). PMID: 28710283
5. Altogether, this preclinical study demonstrates that the tPA present in the blood stream is a key player of the formation of intracranial aneurysms. PMID: 28754830
6. tPA is a ligand of the N-terminal domain of the obligatory GluN1 subunit of NMDAR acting as a modulator of their dynamic distribution at the neuronal surface and subsequent signaling. PMID: 27831563
7. t-PA binds to Lys91 in the MBP NH2-terminal region and PLGbinds to Lys122 in the MBP COOH-terminal region. This proximity promotes the activation of Pg by t-PA. PMID: 28648598
8. local accumulation of cortisol is a causative factor for amnion epithelial apoptosis via activation of tPA/plasmin system toward the end of gestation. This may contribute to the ROM at both term and preterm birth. PMID: 27690691
9. We identified a homozygous null mutation in PLAT that abrogated t-PA level in patient cells. This is the first reported human knockout mutation of PLAT. The apparent association with hydranencephaly, diaphragmatic hernia and postnatal lethality requires further validation. PMID: 27417437
10. Tissue plasminogen activator (t-PA) antigen is a marker of cardiovascular risk. Exercise interventions associated with weight loss reduce t-PA antigen. Endurance training per se reduces t-PA antigen in healthy overweight men. PMID: 28254694
11. we reviewed current knowledge of mechanisms by which tPA can influence brain function in physiological and pathological conditions--REVIEW} PMID: 26626577
12. Data suggest that baseline levels of adiponectin, C-reactive protein, TPA, and fibrinogen or changes in these levels do not explain increased risk of diabetes type 2 in overweight women with glucose intolerance and histories of gestational diabetes. PMID: 25970741
13. Tissue plasminogen activator (tPA) may be a general factor in the immunological response to viruses. PMID: 26704613
14. tPA has a role in progression of periventricular white matter hyperintensities PMID: 26942412
15. These data indicate that oxygen-glucose deprivation-triggered Cav-1 S-nitrosylation interacts with tPA-induced ERK activation to augment MMP2 and 9 secretion and subsequent extracellular matrix degradation. PMID: 26881424
16. tPA-dependent activation of EGFRs leads to downregulation of NMDAR signaling and to subsequent neurotrophic effects. PMID: 26469972
17. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalization may improve safety of thrombolytic therapy. PMID: 25855589
18. Intravenous tissue plasminogen activator therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged>80 years) with acute ischemic stroke. PMID: 25329379
19. Review: t-PA function and regulation of its pericellular activity, with an emphasis on regulation of its gene expression. PMID: 24718307
20. data implicate MCP-1 as the key molecule governing tPA-induced fluid accumulation. The role of MCP-1 in the development of other exudative effusions warrants examination. PMID: 25474480
21. remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients PMID: 24815086
22. The results suggest roles for TLR3, TLR10, PLAT (n=2), VEGFA and DENND1B in susceptibility to chronic cavitary pulmonary aspergillosis. PMID: 24712925
23. shRNA-mediated silencing of PLAT in glioma-initiating cells phenocopied the effects of miR340 overexpression in vitro effects of miR340 overexpression in vitro PMID: 25627976
24. Activation of T cells triggered a rapid, 8.4-fold up-regulation of the serine protease tissue plasminogen activator, the protease target for neuroserpin. PMID: 25670787
25. Report tPA with a cutoff of 8.5 ng/mL has a high sensitivity and negative predictive value for exclusion of pulmonary embolism. PMID: 25339163
26. Data indicate that binding of tissue-type plasminogen activator (t-PA) to glucose-regulated protein 78 (GRP78) stimulates its amidolytic activity, activation of plasminogen (Pg), and cell proliferation. PMID: 25059665
27. Obese men exhibited lower levels of TPA activity compared to normal weight men. PMID: 25306554
28. plasminogen and plasmin but not tissue-type plasminogen activator have roles in regulating fibrinolysis by C-terminal lysines PMID: 22974122
29. It is involved in Amyloid-beta catabolism and clearance, which is particularly efficient for degrading Amyloid-beta aggregates. Thus, endogenous tPA could delay Alzheimer's disease pathogenesis by maintaining low levels of brain Amyloid beta. PMID: 24126163
30. Data suggest that tPA is required for bone repair and osteoblast proliferation; recombinant tPA stimulates proliferation of osteoblastic cell line. PMID: 24918201
31. Endogenously released tPA promotes neutrophil transmigration to reperfused tissue via proteolytic activation of plasmin and gelatinases. PMID: 24764453
32. There are correlations between t-PA, PAI-1 and some rotational thromboelastometry parameters in multiple myeloma patients. PMID: 24964508
33. Identify 3 loci associated with circulating tPA levels, the PLAT region, STXBP5, and STX2. Functional studies implicate a novel role for STXBP5 and STX2 in regulating tPA release. PMID: 24578379
34. Studies suggest that inadequate synthesis and release of tissue plasminogen activator (tPA) or low tPA activity be considered a critical component of schizophrenia pathophysiology. PMID: 24108470
35. Tissue plasminogen activator (t-PA) is a model of preterm intracerebral-intraventricular hemorrhages for the ontogenic window of vascular immaturity and protection against later neurodisabilities. PMID: 24709679
36. Data suggest plasma tissue plasminogen activator (t-PA) and fibrin fragment D-dimer levels are higher in abdominal aortic aneurysm patients than in controls; however, there is a negative relationship between t-PA and intraluminal thrombus thickness. PMID: 23959729
37. LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein. PMID: 24129569
38. Renal impairment is associated with higher risk of symptomatic intracranial hemorrhage (sICH) after administration of intravenous tPA. PMID: 24145699
39. Successful thrombolysis can resolve DWI lesions but does not always improve the neurological symptoms. PMID: 21848677
40. Excess tissue-type plasminogen activator causes targeted Purkinje cell degeneration and ataxia. PMID: 23939410
41. II genotype carrier osteomyelitis patients had lower PAI-1/tPA complex levels. PMID: 23570848
42. Intravenous thrombolysis with alteplase does not appear to increase the risk of hemorrhagic complications in these non-metastatic cancer patients, in absence of additional risk factors of bleeding. PMID: 23317922
43. The combination of recombinant PA and erythropoietin increases release of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and thereby potentially deteriorates ischemic stroke outcome. PMID: 23788583
44. Use of intraventricular tPA for aneurysmal subarachnoid hemorrhage surgery results in less vasospasm, fewer angioplasties, and fewer cerebrospinal fluid shunting procedures. PMID: 20559098
45. Persons who develop non-affective psychoses have lower levels of certain acute phase proteins, including tPA, at the time of birth. PMID: 23423137
46. This meta-analysis suggested that the -7351C/T polymorphism in TPA gene would be a risk factor for ischemic stroke. PMID: 23326456
47. These results suggest that retained tPA on vascular endothelial cells effectively activated plasminogen to plasmin. PMID: 23118500
48. The serine protease tissue plasminogen activator (tPA) and two matrix metalloproteinases, ADAMTS-4 and ADAMTS-5, were identified as Reelin cleaving enzymes. PMID: 23082219
49. Intraventricular fibrinolysis with recombinant tPA does not lead to increased perihemorrhagic edema after intracerebral hemorrhage. PMID: 23306318
50. VDAC binds tissue-type plasminogen activator (t-PA) on human neuroblastoma SK-N-SH cells PMID: 23161549
顯示更多

收起更多
相關疾病：

Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
亞細胞定位：

Secreted, extracellular space.
蛋白家族：

Peptidase S1 family
組織特異性：

Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
數據庫鏈接：

HGNC: 9051

OMIM: 173370

KEGG: hsa:5327

STRING: 9606.ENSP00000220809

UniGene: Hs.491582